Trial Search Results

Study in Subjects With Small Primary Choroidal Melanoma

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Aura Biosciences

Stanford Investigator(s):

Intervention(s):

  • Drug: Light-activated AU-011

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - Diagnosis of choroidal melanoma

Exclusion Criteria:

   - Have known contraindications or sensitivities to the study drug

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mariana Nunez
650-497-7846
Recruiting